Why did Nvidia's stock surge on US-Saudi AI deal?
How will US-Saudi $600B investment impact tech?
What caused UnitedHealth CEO to step down?
Why is Microsoft laying off 3% workforce now?
How did US-China tariff truce affect markets?
What led to Honda postponing Canadian EV project?
Why did Coinbase rise on S&P 500 inclusion?
How are Trump’s tariffs impacting auto and insurance?
What’s behind the surge in student loan delinquencies?
Zepbound beats Wegovy for weight loss in first head-to-head trial of blockbuster drugs
nbcnews.com/health/health-news/zepbound-beats-wegovy-weight-loss-first-head-head-trial-blockbuster-dr-rcna206162
People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy in the first head-to-head study of the blockbuster medications.
Clinical trial participants who took tirzepatide, the drug sold as Zepbound, lost an average of 50…
This story appeared on nbcnews.com, 2025-05-12 00:29:01.618000.